Ironwood Pharmaceuticals logo

Ironwood PharmaceuticalsNASDAQ: IRWD

Profile

Sector:

Healthcare

Country:

United States

IPO:

03 February 2010

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$673.72 M
-72%vs. 3y high
70%vs. sector
-vs. 3y high
-vs. sector
-156%vs. 3y high
8%vs. sector
-68%vs. 3y high
36%vs. sector

Price

after hours | Fri, 15 Nov 2024 21:20:00 GMT
$4.21+$0.10(+2.43%)

Dividend

No data over the past 3 years
$91.59 M$92.50 M
$91.59 M$3.65 M

Analysts recommendations

Institutional Ownership

IRWD Latest News

Ironwood's Q3 Earnings Lag Estimates, Revenues Top, Stock Down
zacks.com08 November 2024 Sentiment: NEUTRAL

IRWD's third-quarter earnings miss estimates while revenues beat the same. The company maintains revenue guidance for 2024.

Ironwood Pharmaceuticals (IRWD) Misses Q3 Earnings Estimates
zacks.com07 November 2024 Sentiment: NEGATIVE

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.12 per share a year ago.

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
businesswire.com24 October 2024 Sentiment: POSITIVE

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ir.

Ironwood (IRWD) Q2 Earnings & Revenues Fall Shy of Estimates
zacks.com09 August 2024 Sentiment: NEGATIVE

Ironwood (IRWD) reports breakeven earnings for second-quarter 2024. Revenues miss estimates.

Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q2
zacks.com08 August 2024 Sentiment: NEUTRAL

Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.17. This compares to earnings of $0.31 per share a year ago.

The Schall Law Firm Starts Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Begin Conversation
accesswire.com28 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Inquiry Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Incurred Losses To Initiate Dialogue
accesswire.com26 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Initiates Probe Into Allegations Against Ironwood Pharmaceuticals Inc And Urges Investors Who Suffered Losses To Initiate Contact
accesswire.com25 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Establish Communication
accesswire.com24 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Begins Investigation Into Claims Against Ironwood Pharmaceuticals Inc And Encourages Investors With Losses To Reach Out
accesswire.com22 June 2024 Sentiment: NEGATIVE

LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ironwood Pharmaceuticals, Inc. ("Ironwood" or "the Company") (NASDAQ:IRWD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

  • 1(current)
  • 2
  • 3

What type of business is Ironwood Pharmaceuticals?

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

What sector is Ironwood Pharmaceuticals in?

Ironwood Pharmaceuticals is in the Healthcare sector

What industry is Ironwood Pharmaceuticals in?

Ironwood Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Ironwood Pharmaceuticals from?

Ironwood Pharmaceuticals is headquartered in United States

When did Ironwood Pharmaceuticals go public?

Ironwood Pharmaceuticals initial public offering (IPO) was on 03 February 2010

What is Ironwood Pharmaceuticals website?

https://www.ironwoodpharma.com

Is Ironwood Pharmaceuticals in the S&P 500?

No, Ironwood Pharmaceuticals is not included in the S&P 500 index

Is Ironwood Pharmaceuticals in the NASDAQ 100?

No, Ironwood Pharmaceuticals is not included in the NASDAQ 100 index

Is Ironwood Pharmaceuticals in the Dow Jones?

No, Ironwood Pharmaceuticals is not included in the Dow Jones index

When was Ironwood Pharmaceuticals the previous earnings report?

No data

When does Ironwood Pharmaceuticals earnings report?

The next expected earnings date for Ironwood Pharmaceuticals is 14 February 2025